Radiopharm Theranostics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Revenue	3.64	3.63	0.3	0.29	-
Revenue Growth (YoY)	116.02%	1114.26%	2.35%	-	-
Cost of Revenue	3.26	3.59	-	-	-
Gross Profit	0.37	0.04	0.3	0.29	-
Selling, General & Admin	16.66	14.64	13.04	12.23	7.64
Research & Development	35.24	27.52	23.09	22.63	7.49
Other Operating Expenses	-5.44	-3.94	11.38	-0.08	5.9
Total Operating Expenses	46.46	38.21	47.51	34.78	21.03
Operating Income	-46.68	-38.17	-47.21	-34.49	-21.03
Interest Expense	-0.13	-0.07	-0.64	-0.09	-9.35
Total Non-Operating Income (Expense)	-0.13	-0.07	-0.64	-0.09	-9.35
Pretax Income	-46.81	-38.24	-47.85	-34.57	-30.38
Provision for Income Taxes	0.14	0.1	0.1	0.04	0.04
Net Income	-46.94	-38.34	-47.95	-34.61	-30.42
Minority Interest in Earnings	-1.28	-	-	-	-
Net Income to Common	-26.97	-38.34	-47.95	-34.61	-30.42
Shares Outstanding (Basic)	10	7	1	1	1
Shares Outstanding (Diluted)	10	7	1	1	1
Shares Change (YoY)	157.88%	438.49%	26.36%	68.74%	-
EPS (Basic)	-5.37	-5.28	-37.23	-33.96	-50.34
EPS (Diluted)	-5.37	-5.28	-37.23	-33.96	-50.34
Free Cash Flow	-7.03	-36.65	-22.98	-23.25	-9.91
Free Cash Flow Per Share	-0.72	-5.28	-17.84	-22.80	-16.40
Gross Margin	10.27%	1.08%	100.00%	100.00%	-
Operating Margin	-1283.96%	-1050.63%	-15777.20%	-11796.10%	-
Profit Margin	-1291.31%	-1055.27%	-16024.30%	-11838.60%	-
FCF Margin	-193.30%	-1008.57%	-7678.40%	-7951.56%	-
EBITDA	-46.68	-35.58	-44.08	-31.19	-18.04
EBITDA Margin	-1283.96%	-979.19%	-14732.40%	-10668.60%	-
EBIT	-46.68	-38.17	-47.21	-34.49	-21.03
EBIT Margin	-1283.96%	-1050.63%	-15777.20%	-11796.10%	-
Effective Tax Rate	-0.29%	-0.27%	-0.20%	-0.11%	-0.15%

SEC Filings: 10-K · 10-Q